Cargando…

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia, insulin resistance, and/or progressive loss of β-cell function. T2DM patients are at increased risk of micro- and macrovascular disease, and are often considered as representing an atherosclerotic coronary heart disease (CHD) risk eq...

Descripción completa

Detalles Bibliográficos
Autor principal: Bays, Harold E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094576/
https://www.ncbi.nlm.nih.gov/pubmed/25045281
http://dx.doi.org/10.2147/IJGM.S65148
_version_ 1782325857491091456
author Bays, Harold E
author_facet Bays, Harold E
author_sort Bays, Harold E
collection PubMed
description Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia, insulin resistance, and/or progressive loss of β-cell function. T2DM patients are at increased risk of micro- and macrovascular disease, and are often considered as representing an atherosclerotic coronary heart disease (CHD) risk equivalent. Interventions directed at glucose and lipid level control in T2DM patients may reduce micro- and macrovascular disease. The optimal T2DM agent is one that lowers glucose levels with limited risk for hypoglycemia, and with no clinical trial evidence of worsening CHD risk. Lipid-altering drugs should preferably reduce low-density lipoprotein cholesterol and apolipoprotein B (apo B) and have evidence that the mechanism of action reduces CHD risk. Statins reduce low-density lipoprotein cholesterol and apo B and have evidence of improving CHD outcomes, and are thus first-line therapy for the treatment of hypercholesterolemia. In patients who do not achieve optimal lipid levels with statin therapy, or who are intolerant to statin therapy, add-on therapy or alternative therapies may be indicated. Additional available agents to treat hypercholesterolemic patients with T2DM include bile acid sequestrants, fibrates, niacin, and ezetimibe. This review discusses the use of these alternative agents to treat hypercholesterolemia in patients with T2DM, either as monotherapy or in combination with statin therapy.
format Online
Article
Text
id pubmed-4094576
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40945762014-07-18 Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus Bays, Harold E Int J Gen Med Review Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia, insulin resistance, and/or progressive loss of β-cell function. T2DM patients are at increased risk of micro- and macrovascular disease, and are often considered as representing an atherosclerotic coronary heart disease (CHD) risk equivalent. Interventions directed at glucose and lipid level control in T2DM patients may reduce micro- and macrovascular disease. The optimal T2DM agent is one that lowers glucose levels with limited risk for hypoglycemia, and with no clinical trial evidence of worsening CHD risk. Lipid-altering drugs should preferably reduce low-density lipoprotein cholesterol and apolipoprotein B (apo B) and have evidence that the mechanism of action reduces CHD risk. Statins reduce low-density lipoprotein cholesterol and apo B and have evidence of improving CHD outcomes, and are thus first-line therapy for the treatment of hypercholesterolemia. In patients who do not achieve optimal lipid levels with statin therapy, or who are intolerant to statin therapy, add-on therapy or alternative therapies may be indicated. Additional available agents to treat hypercholesterolemic patients with T2DM include bile acid sequestrants, fibrates, niacin, and ezetimibe. This review discusses the use of these alternative agents to treat hypercholesterolemia in patients with T2DM, either as monotherapy or in combination with statin therapy. Dove Medical Press 2014-07-05 /pmc/articles/PMC4094576/ /pubmed/25045281 http://dx.doi.org/10.2147/IJGM.S65148 Text en © 2014 Bays. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Bays, Harold E
Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
title Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
title_full Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
title_fullStr Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
title_full_unstemmed Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
title_short Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
title_sort lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094576/
https://www.ncbi.nlm.nih.gov/pubmed/25045281
http://dx.doi.org/10.2147/IJGM.S65148
work_keys_str_mv AT baysharolde loweringlowdensitylipoproteincholesterollevelsinpatientswithtype2diabetesmellitus